regarding information needed by Campaign audiences as well as their attitudes and behaviors related to COVID–19 and the COVID–19 vaccines. These will be used to inform the development of Campaign messages and strategy.

**Copy Testing Surveys**

Prior to placing Campaign advertisements in market, ASPA will conduct copy testing surveys to ensure the final Campaign messages have the intended effect on target attitudes and behaviors. Copy testing surveys will be conducted with sample members who comprise the target audiences; these surveys will assess perceived effectiveness of the advertisements as well as the effect of exposure to an ad on key attitudes and behavioral intentions. The results from these surveys will be used internally by ASPA to inform decisions on Campaign messages and materials; for example, to identify revisions to the materials or determine which advertisement to move to market.

**Need and Proposed Use:** In light of the current COVID–19 crisis, this information is needed given the impact of the pandemic on the nation. The Secretary of the Department of Health and Human Services (HHS) has declared a public health emergency effective January 27, 2020, under section 319 of the Public Health Service Act (42 U.S.C. 247d [1]) and renewed it continually since its issuance (see links to the determination here and here). Additionally, in accordance with 5 CFR 1320.13, HHS previously requested emergency submissions (sections 1320 (a)(2)(ii) and (2)(iii) of the federal regulations.

### ESTIMATED ANNUALIZED BURDEN HOUR TABLE

<table>
<thead>
<tr>
<th></th>
<th>CET</th>
<th>Foundational focus groups</th>
<th>Copy testing survey</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hours to screen</td>
<td>N/A</td>
<td>0.09</td>
<td>0.03</td>
</tr>
<tr>
<td>Screening participates (per wave)</td>
<td>N/A</td>
<td>2,500</td>
<td>6,700</td>
</tr>
<tr>
<td>Screening participants (total/screened out)</td>
<td>N/A</td>
<td>20,000/19,136</td>
<td>53,600/45,600</td>
</tr>
<tr>
<td>Hours to complete survey/group</td>
<td>0.12</td>
<td>1.5</td>
<td>0.33</td>
</tr>
<tr>
<td>Participants (per wave/round)</td>
<td>1,000</td>
<td>108</td>
<td>1,000</td>
</tr>
<tr>
<td>Number of waves/rounds</td>
<td>92</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Burden per wave/round</td>
<td>120</td>
<td>387</td>
<td>330</td>
</tr>
<tr>
<td>Total participants</td>
<td>92,000</td>
<td>864</td>
<td>8,000</td>
</tr>
<tr>
<td>Total respondents *</td>
<td>92,000</td>
<td>20,000</td>
<td>53,600</td>
</tr>
<tr>
<td>Total burden hours</td>
<td>11,040</td>
<td>3,096</td>
<td>4,248</td>
</tr>
</tbody>
</table>

*Total respondents = total participants for each effort + total people screened out.

### Sum of All Studies

**Total Respondents:** 165,600.

**Total Burden Hours:** 18,384.

### DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### National Institutes of Health

**National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** National Institute of Allergy and Infectious Diseases; Special Emphasis Panel; Integrated Preclinical/ Clinical AIDS Vaccine Development Program (IPCAVD) (U19 Clinical Trial Not Allowed).

**Agenda:**

- To review and evaluate grant applications.
- To inform decisions on Campaign strategies.
- To assess the effectiveness of the advertisements on the target audiences.

**Date:** May 28, 2021.

**Time:** 10:00 a.m. to 5:00 p.m.

**Place:** National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3G36, Rockville, MD 20892 (Virtual Meeting).

**Contact Person:** Poonam Pegg, Ph.D., Scientific Review Officer, Scientific Review Program, DEA/NIAID/NIH/DHHS, 5601 Fishers Lane, MSC–9823, Rockville, MD 20892, 240–292–0719, ppoonam.pegg@nih.gov.

**Catalogue of Federal Domestic Assistance Program Nos.**
- 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research; 87.002, National Institutes of Health, HHS)

**Dated:** May 28, 2021.

**Tyeshia M. Roberson,**
Program Analyst, Office of Federal Advisory Committee Policy.

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**National Institute on Alcohol Abuse and Alcoholism; Notice of Closed Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6). Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** National Institute on Alcohol Abuse and Alcoholism Special Emphasis Panel; Alcohol Abuse and Alcoholism Public Health Initiatives, (AA 21–002, AA 21–003 and AA21–004).

**Agenda:**

- To review and evaluate grant applications.
- To discuss the implications of the current COVID–19 crisis for alcohol misuse.

**Date:** July 15–16, 2021.

**Time:** 9:00 a.m. to 6:00 p.m.